Regulatory
September 24, 2026
For applicable clinical trials running in the EU that meet the relevant requirements, CellCarta's may perform in-house IVD testing under Article 5(5) of the IVDR, which may accelerate your clinical trial timelines and reduce regulatory complexity and cost without sacrificing quality. In this one-pager, learn more about the advantages of this pathway, as well as the other routes through which we support clinical trial testing.
Disclaimer: The views expressed in this article are CellCarta's own and should not be interpreted as having been assessed, endorsed, or validated by the FAMHP.
